<DOC>
	<DOCNO>NCT00006049</DOCNO>
	<brief_summary>RATIONALE : Some tumor need growth factor produce body 's white blood cell keep grow . ZD 1839 may interfere growth factor stop tumor grow . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether combination chemotherapy effective without ZD 1839 non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without ZD 1839 treat patient stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>ZD 1839 Plus Chemotherapy Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare 1 year survival rate , time worsen disease relate symptom , progression free survival chemotherapy naive patient stage IIIB IV non-small cell lung cancer treat one two dos ZD 1839 placebo combine paclitaxel carboplatin . II . Compare quality life patient treat three regimen . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients randomize one three treatment arm . All patient receive paclitaxel IV 3 hour follow carboplatin IV 15-30 minute day 1 . Patients receive low dose oral ZD 1839 ( arm I ) , high dose oral ZD 1839 ( arm II ) , placebo ( arm III ) twice day 1 , daily thereafter . Chemotherapy repeat every 3 week maximum 6 course . ZD 1839 placebo continue daily absence disease progression unacceptable toxicity . Quality life assess prior study , every 3 week completion chemotherapy , every 4 week completion oral ZD 1839 placebo , every 8 week thereafter . Patients follow every 8 week . PROJECTED ACCRUAL : A total 1,029 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonsmall cell lung cancer Stage III disease curable surgery radiotherapy OR Stage IV disease Chemotherapy naive PATIENT CHARACTERISTICS : Age : 18 Performance status : 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 2,000/mm3 WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : ALT AST great 2.5 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No evidence severe uncontrolled cardiovascular disease Pulmonary : No evidence severe uncontrolled pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : No concurrent therapy may interfere evaluation response Radiotherapy : See Disease Characteristics Prior localize irradiation allow Surgery : See Disease Characteristics Prior surgery allow Other : No concurrent drug know significant cytochrome P450 3A4 inhibitory effect ( e.g. , ketoconazole , itraconazole , troleandomycin , erythromycin , diltiazem , verapamil ) No concurrent use contact lens</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>